Latest news with #MarkS.Ordan
Yahoo
06-05-2025
- Business
- Yahoo
Pediatrix Medical Group (NYSE:MD) Posts Better-Than-Expected Sales In Q1 But Stock Drops
We can dig further into the company's revenue dynamics by analyzing its same-store sales, which show how much revenue its established locations generate. Over the last two years, Pediatrix Medical Group's same-store sales averaged 3.5% year-on-year growth. Because this number is better than its revenue growth, we can see its sales from existing locations are performing better than its sales from new locations. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Pediatrix Medical Group's recent performance shows its demand has slowed as its revenue was flat over the last two years. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Pediatrix Medical Group grew its sales at a tepid 2% compounded annual growth rate. This was below our standards and is a tough starting point for our analysis. With a network of approximately 2,620 affiliated physicians caring for some of the most vulnerable patients, Pediatrix Medical Group (NYSE:MD) provides specialized physician services focused on neonatal, maternal-fetal, pediatric cardiology and other pediatric subspecialty care across 37 states. 'Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong first quarter performance, we are raising our full year 2025 Adjusted EBITDA outlook from a range of $215 million to $235 million to a range of $220 million to $240 million, demonstrating our commitment to delivering value for our stakeholders,' said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. EBITDA guidance for the full year is $230 million at the midpoint, above analyst estimates of $226.9 million Is now the time to buy Pediatrix Medical Group? Find out in our full research report . Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported Q1 CY2025 results topping the market's revenue expectations , but sales fell by 7.4% year on year to $458.4 million. Its non-GAAP profit of $0.33 per share was 36.7% above analysts' consensus estimates. Story Continues Pediatrix Medical Group Same-Store Sales Growth This quarter, Pediatrix Medical Group's revenue fell by 7.4% year on year to $458.4 million but beat Wall Street's estimates by 1.6%. Looking ahead, sell-side analysts expect revenue to decline by 5% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Operating margin is a key measure of profitability. Think of it as net income - the bottom line - excluding the impact of taxes and interest on debt, which are less connected to business fundamentals. Pediatrix Medical Group was profitable over the last five years but held back by its large cost base. Its average operating margin of 4.5% was weak for a healthcare business. Analyzing the trend in its profitability, Pediatrix Medical Group's operating margin decreased by 9.2 percentage points over the last five years. This performance was caused by more recent speed bumps as the company's margin fell by 10.9 percentage points on a two-year basis. We're disappointed in these results because it shows its expenses were rising and it couldn't pass those costs onto its customers. Pediatrix Medical Group Trailing 12-Month Operating Margin (GAAP) In Q1, Pediatrix Medical Group generated an operating profit margin of 7%, up 3.8 percentage points year on year. This increase was a welcome development, especially since its revenue fell, showing it was more efficient because it scaled down its expenses. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Sadly for Pediatrix Medical Group, its EPS declined by 1.9% annually over the last five years while its revenue grew by 2%. This tells us the company became less profitable on a per-share basis as it expanded. Pediatrix Medical Group Trailing 12-Month EPS (Non-GAAP) We can take a deeper look into Pediatrix Medical Group's earnings to better understand the drivers of its performance. As we mentioned earlier, Pediatrix Medical Group's operating margin improved this quarter but declined by 9.2 percentage points over the last five years. Its share count also grew by 3.2%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders. Pediatrix Medical Group Diluted Shares Outstanding In Q1, Pediatrix Medical Group reported EPS at $0.33, up from $0.20 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Pediatrix Medical Group's full-year EPS of $1.62 to shrink by 4%. Key Takeaways from Pediatrix Medical Group's Q1 Results We were impressed by how Pediatrix Medical Group blew past analysts' same-store sales, revenue, EPS, and EBITDA expectations this quarter. We were also excited it lifted its full-year EBITDA guidance, topping Wall Street's estimates. Zooming out, we think this was a solid print, but shares traded down 6.3% to $12.11 immediately following the results. Is Pediatrix Medical Group an attractive investment opportunity right now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free.
Business Wire
06-05-2025
- Business
- Business Wire
Pediatrix Medical Group Reports First Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. 'Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong first quarter performance, we are raising our full year 2025 Adjusted EBITDA outlook from a range of $215 million to $235 million to a range of $220 million to $240 million, demonstrating our commitment to delivering value for our stakeholders,' said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. 'While we are raising our guidance, we remain mindful of the uncertainty that we face in the healthcare industry and the broad economic turbulence that is challenging virtually all companies.' Operating Results– Three Months Ended March 31, 2025 Pediatrix's net revenue for the three months ended March 31, 2025 was $458.4 million, compared to $495.1 million for the prior-year period. This decrease reflects the impact of non-same unit activity, primarily practice dispositions, partially offset by growth in same-unit net revenue of 6.2 percent. Same-unit revenue from net reimbursement-related factors increased by 4.6 percent for the 2025 first quarter as compared to the prior-year period. This increase primarily reflects improved payor mix and modest improvements in hospital contract administrative fees. The percentage of services reimbursed by commercial and other non-government payors increased by approximately 120 basis points compared to the prior year period. Same-unit revenue attributable to patient volume increased by 1.6 percent for the 2025 first quarter as compared to the prior-year period. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three months ended March 31, 2025. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.) For the 2025 first quarter, practice salaries and benefits expense was $337.0 million, compared to $369.1 million for the prior-year period. This comparison primarily reflects the impact of practice disposition activity, partially offset by increases in same-unit clinical compensation costs, including incentive compensation based on practice results. For the 2025 first quarter, general and administrative expenses were $58.6 million, as compared to $60.2 million for the prior-year period. This decrease primarily reflects net staffing reductions, partially offset by increases in certain professional services and information technology expenses. For 2025 first quarter, transformational and restructuring related expenses were $6.6 million, compared to $8.5 million for the prior-year period. The expenses in both periods were primarily related to position eliminations and revenue cycle management transition activities. Adjusted EBITDA, which is defined as earnings before interest, taxes, depreciation and amortization and transformational and restructuring related expenses, was $49.2 million for the 2025 first quarter, compared to $37.2 million for the prior-year period. The increase in Adjusted EBITDA was primarily due to the net favorable impacts from same-unit results and practice disposition activity completed during 2024. Depreciation and amortization expense was $5.3 million for the first quarter of 2025, compared to $10.3 million for same period in 2024. This comparison was primarily related to a decrease in depreciation expense related to non-same unit activity, primarily practice dispositions. Interest expense was $9.2 million for the first quarter of 2025, compared to $10.6 million for the first quarter of 2024. Investment and other income was $4.7 million for the first quarter of 2025, compared to $2.0 million for the prior year period. The increase was primarily related to interest income earned on cash balances. Pediatrix generated net income of $20.7 million, or $0.24 per diluted share, for the 2025 first quarter, based on a weighted average 85.4 million shares outstanding. This compares with net income of $4.0 million, or $0.05 per diluted share, for the 2024 first quarter, based on a weighted average 83.3 million shares outstanding. For the first quarter of 2025, Pediatrix reported Adjusted EPS of $0.33, compared to $0.20 for the first quarter of 2024. For these periods, Adjusted EPS is defined as diluted income per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, transformational and restructuring related expenses, and discrete tax events. Financial Position and Cash Flow – Continuing Operations Pediatrix had cash and cash equivalents of $99.0 million at March 31, 2025, compared to $229.9 million at December 31, 2024, and net accounts receivable at March 31, 2025 were $242.5 million. For the first quarter of 2025, Pediatrix used cash of $116.1 million to fund continuing operations, compared to a use of $122.6 million during the first quarter of 2024. Pediatrix typically uses cash during the first quarter of each year as it pays incentive compensation, primarily to its affiliated physicians, and makes employee benefit plan matching contributions that were accrued during the prior year. Additionally, during the first quarter of 2025, the Company used $3.3 million to fund capital expenditures. At March 31, 2025, Pediatrix had total debt outstanding of $611 million, consisting of its $400 million in 5.375% Senior Notes due 2030 and $211 million in borrowings under its Term A Loan. At March 31, 2025, the Company had no outstanding borrowings under its $450 million revolving line of credit. Updated 2025 Outlook As a result of the strong first quarter 2025 performance, Pediatrix is raising its full year 2025 outlook for Adjusted EBITDA, as defined above, and now anticipates Adjusted EBITDA will be in a range of $220 million to $240 million. Non-GAAP Measures A reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three months ended March 31, 2025 and 2024 is provided in the financial tables of this press release. Earnings Conference Call Pediatrix will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company's Website, A replay of the conference call will also be available at ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group's high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,400 affiliated physicians and other clinicians. To learn more about Pediatrix, visit or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company's objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as 'believe,' 'hope,' 'may,' 'anticipate,' 'should,' 'intend,' 'plan,' 'will,' 'expect,' 'estimate,' 'project,' 'positioned,' 'strategy' and similar expressions, and are based on assumptions and assessments made by the Company's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled 'Risk Factors', as well the Company's current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the Company's practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the impact of the Company's termination of its then third-party revenue cycle management provider and transition to a hybrid revenue cycle management model with one or more new third-party service providers, including any transition costs associated therewith; the impact of surprise billing legislation; the effects of economic conditions on the Company's business; the effects of the Affordable Care Act and potential healthcare reform; the Company's relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company's ability to comply with the terms of its debt financing arrangements; the impact of management transitions; the timing and contribution of future acquisitions or organic growth initiatives; the effects of share repurchases; and the effects of the Company's transformation initiatives, including its reorientation on, and growth strategy for, its hospital based and maternal fetal businesses. Pediatrix Medical Group, Inc. Reconciliation of Net Income to Adjusted EBITDA (in thousands) (Unaudited) Three Months Ended March 31, 2025 2024 Net income $ 20,737 $ 4,035 Interest expense 9,154 10,599 Income tax provision 7,353 3,789 Depreciation and amortization expense 5,332 10,308 Transformational and restructuring related expenses 6,605 8,480 Adjusted EBITDA $ 49,181 $ 37,211 Expand Pediatrix Medical Group, Inc. Reconciliation of Diluted Net Income per Share to Adjusted Income per Diluted Share ('Adjusted EPS') (in thousands, except per share data) (Unaudited) Three Months Ended March 31, 2025 2024 Weighted average diluted shares outstanding 85,430 83,275 Net income and diluted net income per share $ 20,737 $ 0.24 $ 4,035 $ 0.05 Adjustments (1): Amortization (net of tax of $430 and $863) 1,290 0.01 2,589 0.03 Stock-based compensation (net of tax of $573 and $716) 1,720 0.02 2,146 0.03 Transformational and restructuring expenses (net of tax of $1,651 and $2,120) 4,954 0.06 6,360 0.08 Net impact from discrete tax events (175 ) — 1,676 0.01 (1) A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended March 31, 2025 and 2024. Expand Pediatrix Medical Group, Inc. Balance Sheet Highlights (in thousands) (Unaudited) As of March 31, 2025 As of December 31, 2024 Assets: Cash and cash equivalents $ 98,978 $ 229,940 Investments 120,198 118,566 Accounts receivable, net 242,529 259,990 Other current assets 29,965 31,111 Intangible assets, net 10,387 11,595 Operating and finance lease right-of-use assets 39,866 39,267 Goodwill, other assets, property and equipment 1,451,556 1,462,231 Total assets $ 1,993,479 $ 2,152,700 Liabilities and shareholders' equity: Accounts payable and accrued expenses $ 234,173 $ 398,690 Total debt, including finance leases, net 612,604 617,664 Operating lease liabilities 42,712 44,649 Other liabilities 314,802 326,759 Total liabilities 1,204,291 1,387,762 Total shareholders' equity 789,188 764,938 Total liabilities and shareholders' equity $ 1,993,479 $ 2,152,700 Expand Pediatrix Medical Group, Inc. Reconciliation of Net Income to Forward-Looking Adjusted EBITDA (in thousands) (Unaudited) Year Ended December 31, 2025 Net income $ 106,210 $ 120,810 Interest expense 36,870 36,870 Income tax provision 39,280 44,680 Depreciation and amortization expense 26,060 26,060 Transformational and restructuring related expenses 11,580 11,580 Adjusted EBITDA $ 220,000 $ 240,000 Expand
